Migraine Treatment Cost in India: A Clinical Cost Breakdown

This piece breaks the real migraine cost drivers apart across acute therapy, preventive therapy and diagnostics, then covers where the biggest bill actually comes from. It closes on what a hospital pharmacy needs to stock to capture that spend rather than lose it to an outside chemist.

How common and costly is migraine in India, really?

Migraine's 1-year prevalence in India runs at 25.2% in the best available population study, nearly double the global average of 14.7%. Women are affected far more than men. That prevalence alone explains why migraine drug volume matters to any hospital or clinic pharmacy serving a general OPD.

The same community-based Karnataka study found migraine sufferers lost 5.8% of their productive time to the condition, translating to roughly four working days a year per patient. Direct migraine cost for healthcare was comparatively small at a mean of ₹112. That low figure reflects undertreatment more than low disease cost, since willingness to pay nearly doubled the actual spend.

What does acute migraine drug therapy cost?

Acute attack therapy is the cheapest tier: over-the-counter analgesics (paracetamol, NSAIDs) and generic triptans form the backbone, and both are off-patent, multi-source generics with retail prices typically in the tens of rupees per tablet through the open market and lower still through Jan Aushadhi generic outlets. Cost per attack for most patients on first-line therapy stays low.

The bigger acute-therapy cost driver is drug class, not brand. Triptan-class drugs (sumatriptan, rizatriptan) cost more per tablet than plain analgesics but are still generically manufactured in India by multiple companies, keeping per-unit prices well below what a single-source patented drug would command. Frequent, poorly-controlled attacks that push a patient toward repeat ER visits or repeat imaging are what actually inflate the bill, not the tablet price itself.

What does preventive (prophylactic) therapy cost?

Prophylactic drugs used for migraine in India are almost entirely older, off-patent, multi-source generics: propranolol, amitriptyline, topiramate, and flunarizine, each available from numerous domestic manufacturers at low per-strip prices. An Indian consensus statement on amitriptyline specifically recommends it as a first-line prophylactic agent for its efficacy and low migraine cost relative to newer agents, which matters directly for a prescribing clinic weighing what to keep in stock.

Newer preventive classes, CGRP-targeted monoclonal antibodies and gepants, are approved and marketed globally and have begun appearing in India, but they sit at a materially higher price point than the generic prophylactic tier because they are patent-protected, single-source biologics or small molecules rather than multi-source generics. A hospital treating chronic, refractory migraine should expect this tier to dominate any pharmacy cost conversation for that subset of patients, even though it represents a small share of the total migraine caseload.

What do diagnostics and specialist visits add to the bill?

Migraine is a clinical diagnosis under International Headache Society criteria and does not require imaging in a patient with a typical history and normal neurological exam. Imaging cost becomes a real line item only when red-flag features are present: sudden severe onset, a new neurological deficit, or a change in headache pattern that makes a neurologist order an MRI to exclude a secondary cause.

Specialist consultation fees vary by city and hospital tier and are not government-fixed, so no single number applies nationally. A general physician visit costs a fraction of a neurologist consult at a tertiary private hospital. This workup-plus-consult track is where migraine cost genuinely diverges by geography and hospital type, unlike the drug tier, which is fixed by manufacturer pricing nationwide.

Where does the real migraine cost burden sit?

The bulk of migraine cost for most patients sits in the drug tier, not the diagnostic tier, because most patients never need imaging. The table below sets out where each cost driver typically sits and what actually determines its price, useful for a hospital deciding what to stock versus what to refer out.

This table reflects the structural pattern behind migraine cost in India, not a fixed rupee figure for any single product, since manufacturer MRPs shift and vary by brand within the generic tiers above.

Why does migraine drug availability matter to a hospital pharmacy?

Most migraine prescriptions are for cheap, high-turnover generics a pharmacy can stock at negligible carrying cost. These are exactly the drugs that walk out the door to a nearby chemist when a hospital's own pharmacy runs an occasional stockout, and low migraine cost per unit is precisely why that leak is so easy to ignore.

A patient sent outside for a low-cost strip of propranolol rarely comes back for the refill, and the hospital loses both the sale and the follow-up visit tied to it. A managed or in-house hospital pharmacy that keeps the full migraine formulary in stock, covering acute analgesics, generic triptans, and the standard prophylactic set, closes this leak at essentially no incremental cost, since these are exactly the low-value, high-frequency SKUs a well-run in-house pharmacy is built to hold.

Medyzen's managed hospital pharmacy model exists for this category of drug. The broader mechanics of what a hospital loses when a prescription leaves the building are covered in prescription leakage and hospital revenue loss, and the branded-versus-generic economics behind the stocking decision are covered in branded vs generic medicine margins.

Sources

1. 1The burden attributable to headache disorders in India: estimates from a community-based study in Karnataka State — National Institutes of Health, National Library of Medicine
2. 2Indian Consensus on the Role of Amitriptyline in Migraine Prophylaxis — National Institutes of Health, National Library of Medicine
3. 3National Pharmaceutical Pricing Authority — drug price control, Government of India
4. 4Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
5. 5Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
6. 6World Health Organization — Headache disorders — global burden and classification

This article is for informational purposes and is not a substitute for professional medical advice. Cost figures are drawn from cited published sources and vary by product, city and hospital; individual drug prices change over time. Consult a qualified neurologist or physician for diagnosis and treatment decisions.